RBC Life Sciences Reports Second Quarter Results

IRVING, Texas--(Business Wire)--
RBC Life Sciences, Inc. (OTCBB: RBCL) today reported net sales of
$6.89 million for the quarter ended June 30, 2008 compared to net
sales of $7.15 million for the same period last year. The Company's
net earnings in the second quarter of 2008 were $276,000, or $0.01 per
diluted share, compared to net earnings of $510,000, or $0.02 per
diluted share, in the second quarter of 2007.

The Company also reported a six percent increase in net sales to
$13.23 million for the first six months of 2008 compared to net sales
of $12.54 million in the same period last year. The Company's net
earnings were $631,000, or $0.03 per share, in the first six months of
this year compared to net earnings of $835,000, or $0.04 per share, in
the same period last year.

Clinton Howard, CEO of RBC Life Sciences, said, "Sales of Medical
Products continued to grow during the second quarter of 2008,
increasing 32 percent over the same period last year. Second quarter
sales included our first shipments of Medical Products to Brazil under
the exclusive distribution agreement we completed in March of this
year.

"Second quarter results were negatively affected by a delay in
planned shipments to certain international licensees. We were pleased
to see shipping activity begin to return to anticipated levels during
June and July as our licensees increased shipments of our products
into major international markets."

Backlog associated with international orders increased to $11.2
million at June 30, 2008 compared to $6.1 million at March 31, 2008
and $6.4 million at June 30, 2007.

Mr. Howard continued, "Our results were also affected by certain
noteworthy expenses incurred during the second quarter. In June we
sponsored a major event for our North American Associates to provide
training and motivation and to introduce them to our newest marketing
initiatives. This event represented a significant investment in our
Associate base as part of our overall strategy to increase sales and
new Associate recruiting. Also during the quarter, we encountered
expenses associated with the completion of the major improvement and
repair project on our headquarters' building."

RBC Life Sciences develops, manufactures and markets high quality
nutritional supplements and personal care products to a growing
population of consumers seeking wellness and a healthy lifestyle.
Under its MPM Medical brand, RBC also develops and markets to health
care professionals proprietary prescription and nonprescription
products for advanced wound care and pain management. All products are
tested for quality assurance in-house, and by outside independent
laboratories, to comply with regulations in the U.S. and in more than
thirty countries in which the products are distributed. For more
information, visit the Company's Web site at www.rbclifesciences.com.

The statements above, other than statements of historical fact,
may be forward-looking. Actual events will be dependent upon a number
of factors and risks including, but not limited to, changes in plans
by the Company's management, delays or problems in production, changes
in the regulatory process, changes in market trends, and a number of
other factors and risks described from time to time in the Company's
filings with the Securities and Exchange Commission.

-0-
*T
RBC Life Sciences, Inc.
Summary Results of Operations
(in thousands, except per share data)
(unaudited)

Quarters Ended
June 30,
----------------
2008 2007
------- -------

Net sales $ 6,887 $ 7,148
Gross profit 3,697 3,793
Operating profit 501 866
Earnings before income taxes 456 812
Provision for income taxes 180 302
Net earnings 276 510

Earnings per share
Basic $ 0.01 $ 0.03
Diluted $ 0.01 $ 0.02

Weighted average shares outstanding - basic 21,243 20,266
Weighted average shares outstanding - diluted 22,944 21,499

Six Months Ended
June 30,
----------------
2008 2007
------- -------

Net sales $13,234 $12,540
Gross profit 7,199 7,098
Operating profit 1,112 1,458
Earnings before income taxes 1,023 1,345
Provision for income taxes 392 510
Net earnings 631 835

Earnings per share - basic and diluted $ 0.03 $ 0.04

Weighted average shares outstanding - basic 21,179 20,227
Weighted average shares outstanding - diluted 22,920 22,109

*T

-0-
*T
RBC Life Sciences, Inc.
Condensed Balance Sheets
(in thousands)
(unaudited)

June December
30, 31,
2008 2007
------- --------
Assets
Cash and cash equivalents $ 5,373 $ 6,369
Inventories 5,702 4,725
Other current assets 1,857 1,334
------- --------
Total current assets 12,932 12,428
Other assets 6,803 6,730
------- --------
Total assets $19,735 $19,158
======= ========

Liabilities and shareholders' equity
Accounts payable and accrued liabilities $ 2,982 $ 4,431
Deferred revenue 5,736 4,323
Other current liabilities 139 136
------- --------
Total current liabilities 8,857 8,890
Other liabilities 2,568 2,690
Shareholders' equity 8,310 7,578
------- --------
Total liabilities and shareholders' equity $19,735 $19,158
======= ========
*T

RBC Life Sciences, Inc.
Steve Brown, CFO, 972-893-4000
steve.brown@rbclifesciences.com
www.rbclifesciences.com

Copyright Business Wire 2008